NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

Phase 2

Terminated

Conditions: Anaplastic Ependymoma
Ependymoma
Ependymomas

Interventions: Drug: Marizomib

First Posted Date: 2018-11-01

Last Posted Date: 2022-07-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT03727841

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Pinometostat

First Posted Date: 2018-10-30

Last Posted Date: 2024-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT03724084

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Phase 2

Active, not recruiting

Conditions: Glioma
Glioblastoma
High Grage Glioma
Malignant Glioma
Low Grade Glioma

Interventions: Drug: Nivolumab

First Posted Date: 2018-10-24

Last Posted Date: 2025-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 61

Registration Number: NCT03718767

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Phase 3

Active, not recruiting

Conditions: Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Other: Best Practice
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2018-10-19

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 280

Registration Number: NCT03712605

Locations: 🇺🇸
MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸
Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States

and more 551 locations

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Active, not recruiting

Conditions: Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Ovarian Cancer AJCC v8
Stage IIIC Ovarian Cancer AJCC v8
Advanced Melanoma
Advanced Renal Cell Carcinoma
Anatomic Stage III Breast Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection

First Posted Date: 2018-10-16

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT03707574

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States

and more 141 locations

M7824 in People With Recurrent Respiratory Papillomatosis

Phase 2

Completed

Conditions: Human Papilloma Virus
Recurrent Respiratory Papillomatosis
Respiratory Papillomatosis
Laryngeal Papilloma, Recurrent

Interventions: Drug: M7824

First Posted Date: 2018-10-16

Last Posted Date: 2022-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03707587

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Phase 1

Completed

Conditions: Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL
Leukemia Cutis
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Pinometostat

First Posted Date: 2018-10-10

Last Posted Date: 2023-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03701295

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Biological: Daratumumab
Drug: Dexamethasone
Drug: Venetoclax

First Posted Date: 2018-10-10

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03701321

Locations: 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Ibrutinib
Biological: Obinutuzumab
Other: Quality-of-Life Assessment
Drug: Venetoclax

First Posted Date: 2018-10-10

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 720

Registration Number: NCT03701282

Locations: 🇺🇸
The Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 864 locations

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Uproleselan

First Posted Date: 2018-10-10

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 670

Registration Number: NCT03701308

Locations: 🇺🇸
Springfield Clinic, Springfield, Illinois, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Community Cancer Institute, Clovis, California, United States

and more 185 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy